BlackBoxRX
 
We highly recommend enabling Javascript while using the BlackBoxRX site.

Daclatasvir

Risk of Hepatitis B Virus Reactivation in Patients Coninfected with HCV and HBV

  • Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with DAKLINZA. HBV reactivation has been reported in HCV/HBV coinfected patients who were undergoing or had completed treatment with HCV direct-acting antivirals and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Monitor HCV/HBV coinfected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate management for HBV infection as clinically indicated

Patient Counseling Information

Package Inserts

Daclatasvir

Additional Information

PubMed - DAKLINZA

Updated May 2017